Calcitroic Acid.
Research-backed compound with potential health benefits. In your body, it's the final step in breaking down Vitamin D for removal. It's a marker that your body has used and is now excreting Vitamin D.
Reviewed March 2026
- Category
- Compound
What Calcitroic Acid is, and what it does.
- Does it work
- It suits laboratories that need a reference standard for measuring vitamin D turnover. Anyone looking at their own vitamin D is looking at D3 or calcifediol instead.
- How much to take
- Zero. None. Your body makes it when it needs to. Taking it orally serves no purpose.
- Time to feel it
- Nobody has measured a time to effect. It's studied as the endpoint of vitamin D breakdown, not as something people take and track.
- The first dose
- Nothing. It's not a supplement and has no known immediate effects when ingested.
- With regular use
- Unknown and irrelevant. It is not meant for long-term consumption. Don't be a guinea pig.
- How well tolerated
- Completely unknown as an oral supplement. It's a research chemical and a metabolic byproduct for a reason.
- How it feels
- Like absolutely nothing. It is not bioactive in a beneficial way when taken as a supplement.
- The overlooked benefit
- Its level tracks how fast vitamin D is being cleared, which is a separate question from how much you have. Two people with the same status can be turning it over at different speeds.
5 to 15mcg a day is where Calcitroic Acid works.
Source: Vitamin D metabolite research; not a standard supplement
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Calcitroic Acid is documented in the library; the clinical read is in the queue. Nothing about the strength of the research prints until the read is done.
- end product of the CYP24A1 vitamin D clearance pathwayIn vitro study
- weak binding at the vitamin D receptor compared with calcitriolIn vitro study
- marker of vitamin D metabolite turnover, not a measure of vitamin D statusNarrative review
- biliary elimination as a conjugated polar acidAnimal study
Questions people ask about Calcitroic Acid.
- Is Calcitroic Acid better than Vitamin D?
- No. It's the opposite. It's what your body makes to get RID of Vitamin D. Take Vitamin D3 instead.
- What are the benefits of taking Calcitroic Acid?
- None. Zero. It's a waste product. Any site claiming benefits is deeply misleading you.
- Where can I buy it?
- You shouldn't. If you see it for sale for human consumption, it's a major red flag about the brand.
- So it's dangerous?
- It's completely untested for oral use in humans. It's not meant to be a supplement. Avoid.
- Does it help with calcium absorption?
- No, that's Vitamin D's job. This is the cleanup crew that shows up after the party's over.
- Why is it listed as a supplement then?
- Sometimes research chemicals or metabolic markers get incorrectly marketed. That's not how biology works. Steer clear.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Calcitroic acid is the water-soluble end product of the CYP24A1 pathway that breaks down the active vitamin D hormone. Cholecalciferol sits at the top of that same chain, several hydroxylation steps upstream.
Calcifediol is the storage form that is hydroxylated to the active hormone and then degraded through the C24 oxidation route ending in calcitroic acid. The two mark opposite ends of one metabolic sequence.
Calcitroic acid is what the body excretes in bile once the active vitamin D hormone has been inactivated. Its appearance reflects the rate of vitamin D turnover rather than a separate activity.
The hepatic and renal enzymes that hydroxylate vitamin D, and CYP24A1 which starts the route toward calcitroic acid, all depend on magnesium. Magnesium status therefore shapes how quickly the pathway runs in both directions.
The mitochondrial P450 electron chain runs NADPH to FAD-containing ferredoxin reductase to ferredoxin to the P450 heme. Riboflavin supplies the flavin half of that chain, so riboflavin status sits upstream of the whole side-chain oxidation that ends in calcitroic acid. This is settled cofactor biochemistry rather than a tested combination in people. It supports normal vitamin D metabolite turnover, and no dose relationship in humans is being asserted.
Every cytochrome P450 carries a heme iron at its catalytic centre, and adrenodoxin-type ferredoxins carry a 2Fe-2S cluster. Iron availability is therefore structural to the pathway that generates calcitroic acid. The link is textbook enzymology; it is not a claim that iron intake changes measured calcitroic acid in a person. Read it as mechanistic context for why the pathway exists at all.
When calcium supply is generous, parathyroid hormone falls and CYP24A1 expression rises, which pushes more calcitriol down the C24 pathway toward calcitroic acid. When calcium supply is scarce, the opposite balance holds. This is normal endocrine regulation of mineral handling. The relationship describes flux through a pathway, not an effect of supplementing calcitroic acid itself.
A rising phosphate burden increases FGF23 signalling in the kidney, which suppresses 1-alpha-hydroxylase and induces CYP24A1 at the same time. The net result is faster conversion of calcitriol into 24-hydroxylated metabolites and on to calcitroic acid. The direction of travel is well described in mineral physiology. What it explains is turnover, a marker, not a clinical endpoint.
VDR must partner RXR to bind vitamin D response elements, including the ones in the CYP24A1 promoter that set the pace of calcitriol breakdown. Retinoid supply therefore sits in the same transcriptional circuit that determines how quickly calcitroic acid is generated. The interaction is receptor biology observed in cell and molecular work. It is not a statement that either nutrient changes measured calcitroic acid in people.
Calcitriol raises transcription of osteocalcin and matrix Gla protein, and vitamin K2 is what carboxylates those proteins so they can bind mineral. Where calcitriol signalling is brisk, the demand for carboxylation rises with it, and calcitroic acid output tracks the tail end of that signalling. The connection is mechanistic and inferential rather than measured as a pair. Read it as pathway context.
Reports describe boron altering the apparent half-life of circulating vitamin D metabolites, which would in turn shift the rate at which calcitroic acid appears. The observations are associations in small studies and animal models, not a demonstrated cause in humans. No mechanism at the enzyme level has been settled. It belongs on the page as a lead, nothing firmer.
Nothing specific on file for Calcitroic Acid. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Calcitroic Acid actually does.
Calcitroic acid is the water-soluble end product of the C24 oxidation pathway, formed after CYP24A1 hydroxylates calcitriol at carbon 24 and successive oxidations cleave the side chain.
Because the carboxylic acid endpoint has lost the intact side chain, it binds the vitamin D receptor far more weakly than calcitriol and functions as a clearance metabolite rather than a signalling hormone.
Elimination is mainly biliary, with the polar acid conjugated and excreted rather than reabsorbed, which is why it accumulates in bile rather than in tissue.
Concentrations of the acid reflect the pace of vitamin D metabolite turnover and are read as a marker of catabolic flux, not as a measure of vitamin D status or of any clinical outcome.
Where Calcitroic Acid comes from.
This one is made in a lab, in small amounts, so scientists have something exact to measure against. It is a research and testing chemical rather than something produced for capsules.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
Preparation begins from a vitamin D secosteroid scaffold or from synthetic intermediates that carry the same ring system, since no practical plant or animal source concentrates the acid.
The C25 side chain is oxidised and shortened in staged chemistry that mirrors what CYP24A1 does enzymatically, ending in a carboxylic acid at carbon 23.
The product is separated from ring isomers and partially oxidised intermediates by preparative chromatography, since the related metabolites differ by single oxygen atoms.
Identity and content are assigned by mass spectrometry and nuclear magnetic resonance against reference material, because the compound is used as a measurement anchor.
It is supplied as a small-quantity solid or a solvent stock for laboratory assays rather than as a bulk powder for encapsulation.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.